No connection

Search Results

IPHA vs JYNT

IPHA
Innate Pharma S.A.
BEARISH
Price
$1.41
Market Cap
$132.2M
Sector
Healthcare
AI Confidence
90%
JYNT
The Joint Corp.
BEARISH
Price
$8.73
Market Cap
$125.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IPHA
--
JYNT
--
Forward P/E
IPHA
-2.25
JYNT
38.8
P/B Ratio
IPHA
-5.18
JYNT
8.2
P/S Ratio
IPHA
14.69
JYNT
2.28
EV/EBITDA
IPHA
-2.29
JYNT
137.61

Profitability

Gross Margin
IPHA
0.0%
JYNT
79.55%
Operating Margin
IPHA
-689.55%
JYNT
4.25%
Profit Margin
IPHA
0.0%
JYNT
5.3%
ROE
IPHA
--
JYNT
-1.5%
ROA
IPHA
-38.85%
JYNT
-0.78%

Growth

Revenue Growth
IPHA
-46.7%
JYNT
3.1%
Earnings Growth
IPHA
--
JYNT
6276.7%

Financial Health

Debt/Equity
IPHA
--
JYNT
0.13
Current Ratio
IPHA
1.27
JYNT
1.59
Quick Ratio
IPHA
1.14
JYNT
0.81

Dividends

Dividend Yield
IPHA
--
JYNT
--
Payout Ratio
IPHA
0.0%
JYNT
0.0%

AI Verdict

IPHA BEARISH

IPHA exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio of -5.18, indicating negative shareholder equity. The company is experiencing a collapse in top-line growth with revenue declining 46.7% YoY, coupled with an unsustainable operating margin of -689.55%. While analysts maintain a 'strong_buy' rating with a $6.00 target, this is fundamentally disconnected from the current data-driven trajectory of value destruction and operational losses.

Strengths
Strong analyst consensus (Strong Buy) suggesting potential pipeline value not captured in financials
Current ratio of 1.27 provides a minimal short-term liquidity cushion
Recent slight 1-week price recovery (+2.9%)
Risks
Negative Book Value (P/B -5.18) indicating insolvency or severe capital erosion
Catastrophic operating margins (-689.55%)
Significant revenue contraction (-46.7% YoY)
JYNT BEARISH

The Joint Corp. (JYNT) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. Despite a low debt-to-equity ratio, the company suffers from negative ROE (-1.50%) and a staggering 5-year price decline of 83.5%. Valuation is prohibitively high with a Price/Book ratio of 8.20 and a Forward P/E of 38.80, which is not supported by a stagnant revenue growth rate of 3.10%. The massive reported earnings growth is likely a mathematical anomaly resulting from a low base effect rather than sustainable organic growth.

Strengths
Very low Debt/Equity ratio (0.13)
Healthy Current Ratio (1.59)
Strong Gross Margins (79.55%)
Risks
Critical Piotroski F-Score (2/9) signaling fundamental decay
Severe long-term value destruction (-83.5% 5Y return)
Extreme overvaluation relative to book value (P/B 8.20)

Compare Another Pair

IPHA vs JYNT: Head-to-Head Comparison

This page compares Innate Pharma S.A. (IPHA) and The Joint Corp. (JYNT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile